SCHEMBL6420720

SCHEMBL6420720

COC(=O)c1cc(Cl)ccc1/C=C\CO

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 1/20 0.49
SLC6A4 P31645 1/20 0.47
SLC6A3 Q01959 1/20 0.47
RXFP1 Q9HBX9 1/20 0.46
ALDH1A1 P00352 3/20 0.44
HPGD P15428 2/20 0.44
GLA P06280 1/20 0.44
NR4A2 P43354 2/20 0.43
PLA2G2A P14555 2/20 0.43
HTT P42858 1/20 0.42
MEN1 O00255 4/20 0.40
KMT2A Q03164 4/20 0.40
LMNA P02545 2/20 0.40
NPC1 O15118 3/20 0.39
RAB9A P51151 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
POLB P06746 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
MAPT P10636 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6420725 1.00 ABL1 (0.49) ABL1SLC6A4SLC6A3RXFP1ALDH1A1
SCHEMBL6420862 0.90 ABL1 (0.46) ABL1SLC6A4SLC6A3RXFP1ALDH1A1
SCHEMBL6420859 0.90 ABL1 (0.46) ABL1SLC6A4SLC6A3RXFP1ALDH1A1
SCHEMBL27577339 0.81 ALDH1A1 (0.50) ABL1SLC6A4SLC6A3RXFP1ALDH1A1
SCHEMBL31098827 0.80 ABL1 (0.56) ABL1SLC6A4SLC6A3RXFP1ALDH1A1
SCHEMBL2392328 0.80 ABL1 (0.56) ABL1SLC6A4SLC6A3RXFP1ALDH1A1
SCHEMBL6425893 0.79 PLA2G2A (0.42) ABL1SLC6A4SLC6A3RXFP1ALDH1A1
SCHEMBL6425886 0.79 PLA2G2A (0.42) ABL1SLC6A4SLC6A3RXFP1ALDH1A1
SCHEMBL10371766 0.78 BACE1 (0.56) SLC6A4SLC6A3ALDH1A1HPGDGLA
SCHEMBL10371764 0.78 BACE1 (0.56) SLC6A4SLC6A3ALDH1A1HPGDGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050227978-A1 Fibrosis inhibitor SUMITOMO PHARMACEUTICALS CO., LTD. (JP) 2005-10-13 US disclosed
EP-1479384-A1 FIBROSIS INHIBITOR SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2004-11-24 EP disclosed
US-20040209939-A1 Pyrrole derivatives SUMITOMO PHARMACEUTICALS CO., LTD. 2004-10-21 US disclosed
US-6759429-B2 HAVING TRANSFORMING GROWTH FACTOR- BETA INHIBITORY ACTIVITY AND BEING USEFUL AS FIBROSIS INHIBITORS FOR ORGANS OR TISSUES SUMITOMO PHARMACEUTICALS CO., LTD. (JP) 2004-07-06 US disclosed
US-20030181496-A1 Pyrrole derivatives DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2003-09-25 US disclosed
EP-1310485-A1 PYRROLE DERIVATIVES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2003-05-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050227978-A1 Fibrosis inhibitor SMAD3, MMP1, SMAD2 ABL1 1133/4885SLC6A4 4304/4885SLC6A3 4017/4885
US-20030181496-A1 Pyrrole derivatives NCOA1, PKD1, NR3C2 ABL1 2293/4885SLC6A4 4601/4885SLC6A3 4215/4885
US-20040209939-A1 Pyrrole derivatives NCOA1, PKD1, NCOR1 ABL1 2432/4885SLC6A4 4596/4885SLC6A3 4129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.